Diabetic drug Semaglutide linked to potential risk of vision loss: Study

Q: How long will it take to read this news story?

The story "Diabetic drug Semaglutide linked to potential risk of vision loss: Study" has 618 words across 24 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Diabetic drug Semaglutide linked to potential risk of vision loss: Study" was covered 4 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 248 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21603706</li><li>URL: https://beamstart.com/news/diabetic-drug-semaglutide-linked-to-17209366985178</li></ul>

Business Standard Logo Business Standard 4d ago

Diabetic drug Semaglutide linked to potential risk of vision loss: Study - Business Standard

Quick Summary:

Representative Image: Semaglutide is sold under the brand names Wegovy, Rybelsus, and Ozempic by Danish drug major Novo Nordisk.

Among 16,827 patients, 710 had Type 2 diabetes (194 prescribed semaglutide; 516 prescribed non-GLP-1 RA medications).

Semaglutide (Ozempic; Novo Nordisk) was approved by the US Food and Drug Administration (FDA) in December 2017 to treat Type 2 diabetes and in December 2022 to treat obesity (typically at higher doses, as Wegovy by Novo Nordisk).